| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Oncolytics Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Therapeutic and Educational Services Provider
Odan Laboratories is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaSserv is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.